Kinvard is a preclinical biotech with an IV/oral compound targeting gram-negative and positive pathogens, leveraging technology from Harvard University and non-dilutive funding from CARB-X.
Clarametyx is a clinical-stage biotech developing anti-biofilm antibodies for cystic fibrosis and other respiratory infections
Endolytix is using enzymes from bacteriophages to target antibiotic resistant nontuberculous mycobacteria (NTM) that cause chronic lung disease.
FastBack Bio is a biotechnology company with a novel CAR-T platform. FastBack Bio will develop CAR-T therapeutics with a novel co-stimulatory domain, M83, from its in-licensed platform.
Inceptor Bio is developing next-generation cell therapy programs with a focus on chimeric antigen receptor (CAR) constructs.
EnteroBiotix is a clinical-stage Microbiome biotech focused on developing therapeutics for Hepatic Encephalopathy and Graft vs. Host Disease.
Amylyx is a pharmaceutical company dedicated to the development of therapeutics for the treatment of neurodegenerative disorders.